EPI.V - ESSA Pharma Inc.
| Previous Close | 7.52 |
| Open | 7.52 |
| Bid | 8.00 x N/A |
| Ask | 8.40 x N/A |
| Day's Range | 7.52 - 7.52 |
| 52 Week Range | 1.90 - 8.50 |
| Volume | 100 |
| Avg. Volume | 477 |
| Market Cap | 156.602M |
| Beta (5Y Monthly) | 1.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.17 |
| Earnings Date | May 07, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.23 |
- Baystreet
Stocks in play: ESSA Pharma Inc.
Presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 2020 American Association ...
- CNW Group
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
- CNW Group
ESSA Pharma to Present at Jefferies Virtual Healthcare Conference
HOUSTON and VANCOUVER , May 27, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI; ) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Jefferies Virtual Healthcare Conference on Thursday June 4, 2020 at 3:30pm Eastern. R. Parkinson, Chief Executive Officer, will provide a corporate overview of the Company's business and will be available for one-on-one meetings from June 2 - 4 , 2020.
- Simply Wall St.
ESSA Pharma Inc. (CVE:EPI): What Does Its Beta Value Mean For Your Portfolio?
Anyone researching ESSA Pharma Inc. (CVE:EPI) might want to consider the historical volatility of the share price...
- CNW Group
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting
HOUSTON and VANCOUVER , May 15, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's clinical candidate, EPI-7386, at the 2020 Virtual American Urological Association ("AUA") Annual Meeting. In an oral poster presentation titled, "The preclinical characterization and development of EPI-7386, an N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer", a more in-depth preclinical characterization of EPI-7386 including gene expression analyses and the toxicologic profile was presented. Inhibits androgen-induced genes with major similarities but some differences from enzalutamide in a cellular model sensitive to androgen receptor inhibitors.
- CNW Group
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2020
- CNW Group
ESSA Pharma Announces FDA Allowance of the Clinical Investigation of EPI-7386 in Prostate Cancer
VANCOUVER and HOUSTON, April 30, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the U.S. Food and Drug Administration ("FDA") has notified the Company that it may proceed with its proposed clinical investigation of EPI-7386 for the treatment of metastatic castration-resistant prostate cancer ("mCRPC"). ESSA previously announced on March 30th, 2020 that it had filed an Investigational New Drug ("IND") application for EPI-7386 with the FDA.
- CNW Group
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
VANCOUVER and HOUSTON , April 13, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market Sale AgreementSM (the "ATM Sales Agreement") with Jefferies LLC, effective as of April 13, 2020 . Under the ATM Sales Agreement, ESSA may sell its common shares in the capital of the Company from time to time for up to US$35.0 million in aggregate sales proceeds in "at-the-market" transactions.
- CNW Group
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
VANCOUVER and HOUSTON , March 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate its lead clinical candidate, EPI-7386, in a Phase 1 clinical study for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The Company also provided a business update as the COVID-19 situation rapidly evolves.
- Simply Wall St.
ESSA Pharma (CVE:EPI) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- CNW Group
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
HOUSTON and VANCOUVER, Feb. 27, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on February 27, 2020 in Vancouver, British Columbia, Canada (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") set the number of directors at nine and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, Sandy Zweifach, and Ari Brettman to serve in office until the next annual meeting or until their successors are duly elected or appointed.
- CNW Group
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
VANCOUVER and HOUSTON, TX , Feb. 13, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies ...
- CNW Group
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019
- Simply Wall St.
How Many ESSA Pharma Inc. (CVE:EPI) Shares Did Insiders Buy, In The Last Year?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- CNW Group
ESSA Pharma Grants Stock Options
HOUSTON and VANCOUVER, Oct. 30, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Corporation") announced that, pursuant to its stock option plan, it has granted incentive stock options to non – executive members of the Corporation's board of directors to purchase up to an aggregate of 225,000 common shares in the capital of the Corporation (the "Common shares"). The stock options will vest in 36 equal monthly instalments, with the first instalment vesting on the one-month anniversary of the grant date.
- Baystreet
ESSA at 52-Week High on Drug Presentation
ESSA Pharma Inc. (V.EPI) hit a new 52-week high of $5.99, Monday. ESSA presented Monday new preclinical ...
- CNW Group
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
HOUSTON and VANCOUVER , Oct. 28, 2019 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today in ...
- CNW Group
ESSA Announces Changes to its Board of Directors
VANCOUVER and HOUSTON, TX, Oct. 18, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that Ari Brettman has been appointed to the board of the directors of the Company (the "Board") pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences.
- CNW Group
ESSA Pharma Board of Directors Approves Stock Option Plan, RSU Plan and Option Grants
VANCOUVER and HOUSTON, Oct. 7, 2019 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, hereby announces that, pursuant to the Company's existing stock option plan (the "Existing Option Plan"), it has granted incentive stock options ("Options") to certain directors, officers, employees and consultants of the Company to purchase up to an aggregate of 1,441,530 common shares in the capital of the Company (the "Common Shares"). The Options are exercisable on or before October 4, 2029 at the price of US$3.23 per Common share and are granted in accordance with the polices of the TSX Venture Exchange (the "TSXV") and the terms and conditions of the Existing Option Plan.
- CNW Group
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress
HOUSTON and VANCOUVER, Sept. 28, 2019 /CNW/ - ESSA Pharma Inc. (Nasdaq:EPIX - News) (TSXV:EPI.V - News), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today presented new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the 2019 American Urological Association ("AUA") Annual Meeting. In an oral poster presentation titled, "EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer", a deeper preclinical characterization of EPI-7386 was presented.
- CNW Group
ESSA to Present at Ladenburg Thalmann Healthcare Conference
Nasdaq: EPIX) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer announced the Company will be presenting at the Ladenburg Thalmann Helathcare Conference on Tuesday September 24, 2019 at 9:30am EDT at the Sofitel New York City in New York. R. Parkinson, Chief Executive Officer, will provide a corporate overview of the Company's business and will be available for one-on-one meetings from on September 24, 2019. ESSA's Chief Financial Officer, David S. Wood, and Chief Operating Officer, Peter Virsik, will also be in attendance.
- CNW Group
ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million
TSXV: EPI) ("ESSA" or the "Company"), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to its previously announced equity offering, it has closed a public offering of equity securities of the Company in Canada and a concurrent private placement of equity securities in the United States for aggregate gross proceeds of US$36 million (the "Offering"). The Offering was led by Soleus Capital and included RA Capital Management as a new investor.
- CNW Group
IIROC Trading Resumption - EPI
VANCOUVER , Aug. 23, 2019 /CNW/ - Trading resumes in: Company: ESSA Pharma Inc. TSX-Venture Symbol: EPI (all issues) Resumption (ET): 11:15 AM IIROC can make a decision to impose a temporary suspension ...
- CNW Group
IIROC Trading Halt - EPI
VANCOUVER , Aug. 23, 2019 /CNW/ - The following issues have been halted by IIROC: Company: ESSA Pharma Inc. TSX-Venture Symbol: EPI (All Issues) Reason: Pending News Halt Time (ET): 10:38 AM IIROC can ...
